Onglyza tabs 5mg #30

Onglyza pills instruction for use

You can buy Onglyza on this page

Composition

The active ingredient saxagliptin (hydrochloride form) is present in the formulation, as well as additional components: MCC, lactose monohydrate, croscarmellose sodium, magnesium stearate, 1 M hydrochloric acid or 1 M sodium hydroxide solution, dyes.

Form of issue

This medicine is available as a film-coated tablet.
    Tablets of 2.5 mg: the color of the shell is yellow, the tablets are biconvex, round, on one side there is the inscription "2.5", on the other hand - "4214". The inscriptions are marked in blue. Tablets are packed in foil blisters, in cardboard bundles - 3 blisters.
    Tablets 5 mg: the color of the shell pink, pills biconvex, round, on one side the inscription "5", on the other hand - "4215". The inscriptions are marked in blue. Tablets are packed in foil blisters, in cardboard bundles - 3 blisters.

pharmachologic effect of Onglyza

The preparation of Onglyza in the composition has the active substance saxagliptin, which is a very strong selective competitive reversible inhibitor of dipeptidyl peptidase-4.
If the drug is taken by patients who suffer from diabetes, they are inhibited for 24 hours in the activity of the enzyme DPP-4.
After the patient took glucose inside, due to inhibition of DPP-4, a 2-3-fold increase in the concentration of a glucose-dependent insulinotropic polypeptide, a glucagon-like peptide-1, occurs. The concentration of glucagon decreases and the response of the glucose-dependent beta-cell response increases. As a result, the body increases the concentration of insulin and C-peptide.
Owing to the release of insulin by beta cells of the pancreas and the decrease in the release of glucagon from pancreatic alpha cells, fasting glycemia decreases, and postprandial glycemia decreases.
In the process of taking saxagliptin in patients, weight gain is not observed.

Pharmacokinetics and pharmacodynamics

In the body, saksagliptin is absorbed rapidly after administration before meals. After oral administration, about 75% of the dose is absorbed. With blood proteins, saxagliptin and its metabolite are not significantly associated.
The maximum concentration of saxagliptin and its main metabolite is noted in the plasma, respectively, for 2 hours and 4 hours.
On average, the duration of the final half-life and its metabolite is 2.5 hours and 3.1 hours, respectively. It is excreted with bile and with urine.

Indications for use

The medicine of Onglyza is indicated for use in type 2 diabetes mellitus as an additional means for physical activity and dietary nutrition in order to improve glycemic control. Can be assigned in the following capacity:
    for the purpose of monotherapy;
    for starting combined treatment with Metformin;
    as an addition to monotherapy with thiazolidinediones, metformin, sulfonylurea derivatives, if there is no adequate glycemic control in such treatment.

Contraindications

Contraindicated application Onlizy in such cases:
    patients with type 1 diabetes mellitus;
    use of the drug in conjunction with the intake of insulin;
    lactase insufficiency, galactose intolerance, glucose-galactose malabsorption congenital;
    diabetic ketoacidosis;
    pregnancy and lactation;
    Enhanced sensitivity to any of the constituents of the drug.
Carefully prescribe medication for people suffering from moderate and severe renal failure, elderly patients, as well as those taking sulfonylureas.

Side effects

The following side effects occur during the administration of the drug Onglyza:
    urinary tract infection and upper respiratory tract;
    sinusitis;
    gastroenteritis;
    vomiting;
    headache.
Against the background of combined treatment with metformin, nasopharyngitis, headaches may manifest.

instructions for use (Method and dosage)

It should be taken orally, regardless of the period of eating.
If the patient is prescribed monotherapy, he is recommended to take the pill at the rate of 5 mg of saxagliptin once a day.
If a combined treatment is prescribed, it is necessary to take 5 mg of saxagliptin once a day, combining the method with thiazolidinediones and Metformin, with drugs derived from sulfonylureas.
At the beginning of the combined treatment with Metformin, the dose of saxagliptin is 5 mg, and the dose of Metformin is 500 mg per day.
If the patient missed the Onglyza treatment, take the pill immediately, as soon as a person remembers it. A double dose should not be drunk.
Patients with mild renal insufficiency may not adjust the dose. Patients with severe or moderate renal insufficiency, as well as those who are on hemodialysis, should take 2.5 mg of medication per day. You should drink pills after hemodialysis.
If the patient simultaneously uses strong inhibitors of CYP 3A4 / 5, the dose of Onglyza should be 2.5 mg per day.

Overdose

There is no description of the symptoms of intoxication with prolonged intake of large doses of the remedy. In case of an overdose, symptomatic treatment is practiced. From the body, the active substance and its metabolite can be removed by hemodialysis.

Interaction

According to the research data, there is a relatively small risk of clinically significant interaction of saxagliptin with other drugs.
With simultaneous application of CYP 3A4 / 5 isozymes inductors (dexamethasone, carbamazepine, phenobarbital, rifampicin, phenytoin), the concentration of the main metabolite of saxagliptin can decrease.
Since sulfonylureas can provoke hypoglycemia to reduce risk, it may be necessary to reduce the dose of sulfonylureas with simultaneous treatment with Onglyza.

Storage conditions

It is necessary to protect Onglyza from children, while t should not be above 30 ° C.
Shelf life - 3 years.

special instructions

It should be borne in mind that the use of the English medicine together with insulin and in the triple treatment (metformin, thiazolidinediones, sulfonylureas) has not been studied at the moment.
There were no studies on the effect of the drug on the ability to drive vehicles and work with precise mechanisms. Nevertheless, it should be noted that after taking the drug, dizziness may appear.

Children

Not assigned to patients under 18 years of age.

In pregnancy and lactation

Since the use of saxagliptin for the treatment of pregnant women has not been studied, no medication is prescribed for women during fetal gestation. Since there is no data on the penetration of saxagliptin in breast milk, during the period of natural feeding, the Onglis tablets are also not prescribed.

Reviews about Onglyza

In reviews, it is often said that Onglyza allows diabetics to provide effective glucose control. It is noted that the drug is convenient to use, adverse reactions during treatment are rare. A negative point for users is the high cost of the drug.